ContractLicense Agreement • August 9th, 2006 • Cv Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 4 TO THE LICENSE AGREEMENT (“Fourth Amendment”) is made and entered into effective as of June 20, 2006 (“Fourth Amendment Date”) by and between ROCHE PALO ALTO LLC (successor in interest by merger to SYNTEX (U.S.A.) INC.) (“Roche”), having offices at 3431 Hillview Avenue, Palo Alto, California 94304, and CV THERAPEUTICS, INC. (“CVT”), having an address at 3172 Porter Drive, Palo Alto, California 94304. Capitalized Terms used in the Fourth Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the License Agreement.
SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 9th, 2006 • Cv Therapeutics Inc • Biological products, (no disgnostic substances)
This Second Amendment (“Second Amendment”) is effective as of the first (1st) day of January, 2006 (“Effective Date”), by and between Astellas US LLC, successor-in-interest to Fujisawa Healthcare, Inc., the original signatory to the Agreement referenced below (“Astellas”), and CV Therapeutics, Inc. (“CVT”), with Astellas and CVT being individually referred to herein as a “Party” and collectively as the “Parties”.
CV Therapeutics, Inc. requests that the marked portions of the exhibit be granted confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. COLLABORATION AND LICENSE AGREEMENT by and between CV Therapeutics, Inc. and...Collaboration and License Agreement • August 9th, 2006 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of the 6th day of June, 2006 (the “Effective Date”) by and between CV Therapeutics, Inc., a Delaware corporation, having its principal place of business at 3172 Porter Drive, Palo Alto, California 94304 (“CVT”) and PTC Therapeutics, Inc., a Delaware corporation, having its principal place of business at 100 Corporate Court, South Plainfield, New Jersey 07080 (“PTC”). CVT and PTC are each hereafter referred to individually as a “Party” and collectively as the “Parties”.
